Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
In daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma. It acts as an immune checkpoint inhibitor, binding and blocking cytotoxic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2018.00150/full |
| _version_ | 1818412731394424832 |
|---|---|
| author | Vera Montes Sandra Sousa Fernando Pita Rui Guerreiro Cátia Carmona |
| author_facet | Vera Montes Sandra Sousa Fernando Pita Rui Guerreiro Cátia Carmona |
| author_sort | Vera Montes |
| collection | DOAJ |
| description | In daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma. It acts as an immune checkpoint inhibitor, binding and blocking cytotoxic T-lymphocyte antigen-4 in order to increase the antitumor immune response. There are several reports of autoimmune responses after its use. A 74-year-old man developed a mild rash and pruritus a few hours after the second infusion of ipilimumab and 24 h after the third dose of ipilimumab, he presented with shortness of breath, proximal limb muscle weakness, and diplopia. Repetitive nerve stimulation was consistent with a postsynaptic neuromuscular junction disorder. He began therapy with corticosteroids and pyridostigmine and ipilimumab was discontinued. Following ipilimumab suspension, the patient started to improve gradually. Here, we describe a rare case of myasthenia gravis presumably related with ipilimumab’s therapy. A better knowledge of these agents is necessary, in order to identify characteristics or biomarkers that may be associated with the development of potentially serious autoimmune responses. |
| first_indexed | 2024-12-14T10:51:58Z |
| format | Article |
| id | doaj.art-2effad4f2fd741baaefe7e79a76d6446 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-14T10:51:58Z |
| publishDate | 2018-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-2effad4f2fd741baaefe7e79a76d64462022-12-21T23:05:09ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-04-01910.3389/fneur.2018.00150303237Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic MelanomaVera MontesSandra SousaFernando PitaRui GuerreiroCátia CarmonaIn daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma. It acts as an immune checkpoint inhibitor, binding and blocking cytotoxic T-lymphocyte antigen-4 in order to increase the antitumor immune response. There are several reports of autoimmune responses after its use. A 74-year-old man developed a mild rash and pruritus a few hours after the second infusion of ipilimumab and 24 h after the third dose of ipilimumab, he presented with shortness of breath, proximal limb muscle weakness, and diplopia. Repetitive nerve stimulation was consistent with a postsynaptic neuromuscular junction disorder. He began therapy with corticosteroids and pyridostigmine and ipilimumab was discontinued. Following ipilimumab suspension, the patient started to improve gradually. Here, we describe a rare case of myasthenia gravis presumably related with ipilimumab’s therapy. A better knowledge of these agents is necessary, in order to identify characteristics or biomarkers that may be associated with the development of potentially serious autoimmune responses.http://journal.frontiersin.org/article/10.3389/fneur.2018.00150/fullmyastheniaipilimumabimmunitysafetyside effects |
| spellingShingle | Vera Montes Sandra Sousa Fernando Pita Rui Guerreiro Cátia Carmona Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma Frontiers in Neurology myasthenia ipilimumab immunity safety side effects |
| title | Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma |
| title_full | Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma |
| title_fullStr | Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma |
| title_full_unstemmed | Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma |
| title_short | Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma |
| title_sort | myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma |
| topic | myasthenia ipilimumab immunity safety side effects |
| url | http://journal.frontiersin.org/article/10.3389/fneur.2018.00150/full |
| work_keys_str_mv | AT veramontes myastheniagravisinducedbyipilimumabinapatientwithmetastaticmelanoma AT sandrasousa myastheniagravisinducedbyipilimumabinapatientwithmetastaticmelanoma AT fernandopita myastheniagravisinducedbyipilimumabinapatientwithmetastaticmelanoma AT ruiguerreiro myastheniagravisinducedbyipilimumabinapatientwithmetastaticmelanoma AT catiacarmona myastheniagravisinducedbyipilimumabinapatientwithmetastaticmelanoma |